Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Can-Fite BioPharma submitted a Phase 2 clinical study protocol to Bambino Gesù Children's Hospital for the evaluation of Piclidenoson in patients with Lowe syndrome. The open-label study is designed to enroll five adult patients over six months, with the primary endpoint focused on improving renal uptake as a measure of proximal tubular function.
Key figures
- Drug Name
- Piclidenoson
- Phase Of Trial
- Phase 2
- Patients
- 5
- Duration months
- 6
- Partner research investment eur
- 660 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.